Members of the Innovative Pharmaceutical Initiative (iF!) during 2025 recorded at least EUR 26 million in transfers of value to healthcare organizations and healthcare professionals, patient associations, and investments in research and development, enabling patients to access the latest therapies and educating physicians about new and effective treatment methods.

Of the total amount, the innovative pharmaceutical industry in Croatia invested EUR 7.2 million in research and development last year. Transfers of value amounting to at least EUR 9.2 million were made to healthcare professionals, while at least EUR 8.8 million, representing 34% of the total transfer of value, was transferred to healthcare organizations. In accordance with regulations that guarantee the protection of personal data, 17% of physicians voluntarily consented to the individual disclosure of data relating to transfers of value.

Members of iF! have publicly disclosed data on transfers of value to physicians and healthcare organizations as of June 30, in accordance with the requirements of the EFPIA Code on Disclosure of Transfers of Value. This marks the ninth consecutive year that the innovative pharmaceutical industry has practiced this in over 30 countries. The innovative pharmaceutical industry is the first industry in the world to publicly disclose transfer of value data, contributing to transparency in public-private sector collaboration and to a better understanding of the relationship between the industry and healthcare professionals and organizations.

With these funds, the innovative pharmaceutical industry in Croatia has, for example, enabled the implementation of a number of valuable projects by various healthcare organizations through sponsorships and donations, thereby contributing to the improvement of public health in the Republic of Croatia. In addition to the professional development of physicians, the collaboration between the industry and healthcare professionals also involves participation in medical and educational meetings, where physicians provide their expertise, time, and work, for which they receive fair compensation. Research and development refer to the processes of collecting data on the efficacy and safety of specific medicines or medical procedures, and are conducted through clinical studies and collaboration with healthcare organizations, healthcare professionals, and patients.

In addition to the transfer of value itself, research and development activities generate further value through the provision of medicines free of charge, as well as through the education of physicians on new and more effective treatment methods. Recognizing the value and contribution of patient organizations within the healthcare system, the innovative pharmaceutical industry supported the activities of patient associations in a total amount of EUR 665 thousand.